UK MHRA Looks Beyond Brexit Transition
Now that the UK has left the EU, the UK’s medicines regulator says it will use the rest of this year to work out how best to ensure continuity of drug regulation after the Brexit transition period ends on 31 December.
You may also be interested in...
Could the UK carry on playing a part in the European Medicines Agency from 2021? Much will depend on the complex negotiations on the future relationship that are expected to kick off in March.
Some changes have been made to UK legislation that will aim to ensure the effective operation of the regulatory system once the country leaves the EU. Areas affected include the QPPV, pediatric and orphan medicines, and the reference product for generic approvals.